Back to Search
Start Over
Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients
- Source :
- European Journal of Neurology, European Journal of Neurology, 2015, 22 (3), pp.507-e35. ⟨10.1111/ene.12600⟩, European Journal of Neurology, Wiley, 2015, 22 (3), pp.507-e35. ⟨10.1111/ene.12600⟩
- Publication Year :
- 2015
- Publisher :
- HAL CCSD, 2015.
-
Abstract
- International audience; Background and purpose - Multiple sclerosis (MS) prognosis remains a challenge for both patients and physicians. Complementary to natural history studies, updated population-based data from the first event suggestive of MS, at the time of the first approved disease modifying drug (DMD), are needed. Our objective was to provide a 10-year history of MS from clinical onset at time of first approved DMDs in a population-based cohort. Methods - A population-based cohort of patients whose first clinical event suggestive of MS had occurred in Brittany between 2000 and 2001 was prospectively selected. History of relapses, treatments and disability up to 10 years after onset were collected. Results - In all, 278 patients with either attack-onset (n = 244) or progressive-onset (n = 34) were recruited. Amongst attack-onset patients, 30% remained as clinically isolated syndrome and 70% had a second relapse after a median time of 1.7 years (95% confidence interval 1.2-2.4). 80% of relapsing-remitting MS patients received DMDs for at least 6 months. 29% reached disability status scale (DSS) 3 and 8% DSS 6. Amongst progressive-onset patients, 100% reached DSS 3 and 59% DSS 6. Conclusion(s) - Our population-based study reports a lower risk of disability progression at 10-year follow-up in the relapsing-remitting MS group than previously reported. This better prognosis was not observed in the progressive-onset MS group. This finding impacts the prognosis given to patients in clinical practice.
- Subjects :
- Male
Pediatrics
Time Factors
MESH: Multiple Sclerosis, Relapsing-Remitting
Disease
multiple sclerosis
0302 clinical medicine
cohort studies
Recurrence
MESH: Child
Epidemiology
Medicine
demyelinating diseases
10. No inequality
Child
MESH: Aged
0303 health sciences
education.field_of_study
Clinically isolated syndrome
MESH: Middle Aged
MESH: Follow-Up Studies
Middle Aged
Multiple Sclerosis, Chronic Progressive
3. Good health
Natural history
Neurology
MESH: Young Adult
Cohort
Disease Progression
Female
epidemiology
MESH: Disease Progression
[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
Cohort study
Adult
medicine.medical_specialty
Adolescent
Population
MESH: Prognosis
03 medical and health sciences
Young Adult
Multiple Sclerosis, Relapsing-Remitting
Humans
[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
MESH: Multiple Sclerosis, Chronic Progressive
education
030304 developmental biology
Aged
MESH: Adolescent
MESH: Humans
business.industry
Multiple sclerosis
MESH: Time Factors
MESH: Adult
medicine.disease
MESH: Male
MESH: Recurrence
clinically isolated syndrome
Physical therapy
Neurology (clinical)
prognosis
business
MESH: Female
030217 neurology & neurosurgery
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 13515101 and 14681331
- Database :
- OpenAIRE
- Journal :
- European Journal of Neurology, European Journal of Neurology, 2015, 22 (3), pp.507-e35. ⟨10.1111/ene.12600⟩, European Journal of Neurology, Wiley, 2015, 22 (3), pp.507-e35. ⟨10.1111/ene.12600⟩
- Accession number :
- edsair.doi.dedup.....f6f1332f612f25993e7e4a39eae05867